| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/09/2005 | EP1503988A2 Fredericamycin derivatives |
| 02/09/2005 | EP1503803A1 Medicinal formulation in particular for treating herniated invertebral discs |
| 02/09/2005 | EP1503800A1 Treatment and prevention of tissue damage |
| 02/09/2005 | EP1503797A1 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
| 02/09/2005 | EP1503796A1 Compositions and methods for delivery of photosensitive drugs |
| 02/09/2005 | EP1503795A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 02/09/2005 | EP1503794A1 Methods of treatement using ctla-4 antibodies |
| 02/09/2005 | EP1503793A2 Cancer vaccines and methods of using the same |
| 02/09/2005 | EP1503785A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503778A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 02/09/2005 | EP1503777A1 7-hydroxy chromones as potent antioxidants |
| 02/09/2005 | EP1503773A1 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 02/09/2005 | EP1503767A2 Compositions and methods for treatment of vitamin d deficiency |
| 02/09/2005 | EP1503760A1 Camptothecin derivatives and polymeric conjugates thereof |
| 02/09/2005 | EP1503757A2 Tyrosine kinase inhibitors |
| 02/09/2005 | EP1503756A1 Epothilone derivative for the treatment of hepatoma and other cancer diseases |
| 02/09/2005 | EP1503752A1 Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy |
| 02/09/2005 | EP1503751A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1503740A1 Monocompartment osmotic controlled drug delivery system |
| 02/09/2005 | EP1503714A2 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1420802A4 Increased solubility flavanolignan preparations |
| 02/09/2005 | EP1401446B1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
| 02/09/2005 | EP1387683B1 Novel salt and crystalline forms of (2r)-anti-5-3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy quinoline |
| 02/09/2005 | EP1274980A4 Solution and crystal structures of mmp-13 active site and uses thereof |
| 02/09/2005 | EP1255850A4 AMPLIFICATION OF $i(CYP24) AND USES THEREOF |
| 02/09/2005 | EP1210119B1 Pharmaceutical compositions for oral and topical administration |
| 02/09/2005 | EP1162982B1 USE OF STABILISED OLIGONUCLEOTIDES FOR PREPARING A MEDICament WITH ANTITUMOUR ACTIVITY |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | EP1087951B1 Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| 02/09/2005 | EP1056860B1 High affinity humanized anti-tag-72 monoclonal antibodies |
| 02/09/2005 | EP1042316B1 Indole derivatives useful a.o. for the treatment of osteoporosis |
| 02/09/2005 | CN1578840A Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| 02/09/2005 | CN1578786A Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/09/2005 | CN1578781A 1, 8 naphthyridine derivatives and their use to treat diabetes and related disorders |
| 02/09/2005 | CN1578780A 1, 6-naphthyridine derivatives as antidiabetics and pharmaceutical compositions containing them |
| 02/09/2005 | CN1578776A Heterocyclic retinoid compounds |
| 02/09/2005 | CN1578773A Methods and compositions of novel triazine compounds |
| 02/09/2005 | CN1578768A Anthranilic acid amides and pharmaceutical use thereof |
| 02/09/2005 | CN1578767A Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2005 | CN1578688A Method and apparatus for the photomodulation of living cells |
| 02/09/2005 | CN1578677A Improved therapeutic protocols |
| 02/09/2005 | CN1578674A Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 02/09/2005 | CN1578673A Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
| 02/09/2005 | CN1578667A Anticancer compositions |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1578663A Inhibitors of histone deacetylase |
| 02/09/2005 | CN1578661A Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 02/09/2005 | CN1578658A Metal organic antitumour agent |
| 02/09/2005 | CN1578647A Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| 02/09/2005 | CN1578626A Multivesicular emulsion topical delivery systems |
| 02/09/2005 | CN1576840A Methods for diagnosis and therapy of cancer and composition useful therein |
| 02/09/2005 | CN1576277A New derivatives of benzo[a]pyrano[3, 2-h]acridin-7-one, a process for their preparation and pharmaceutical compounds containing them |
| 02/09/2005 | CN1576275A Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 02/09/2005 | CN1575819A Use of melanoma differentiation associated gene (mda-7) for reversing cancerous phenotype |
| 02/09/2005 | CN1188415C Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5)for treatment of sexual dysfunction |
| 02/09/2005 | CN1188407C Imidazole derivatives with farnesyl transferase to inhibite activity and preparing method thereof |
| 02/09/2005 | CN1188405C New Morpholinobenzamide salts |
| 02/09/2005 | CN1188404C Cyclic compound |
| 02/09/2005 | CN1188169C Use of antibodies for anticancer vaccination |
| 02/09/2005 | CN1188158C Medicines composition for raising body's immunity and its prepn |
| 02/09/2005 | CN1188157C Chinese herbal medicine tumor-eliminating drop |
| 02/09/2005 | CN1188153C Medicines for treating cancers and tumours |
| 02/09/2005 | CN1188137C Use of erythrogenin and molecule with active EPO receptor ability or analog EPO activation in pharmacy |
| 02/09/2005 | CN1188134C Preparation having increased in vivo tolerability |
| 02/09/2005 | CN1188127C Nasal cavity administrated prepn for treating cerebral tumor |
| 02/09/2005 | CN1188118C Medicine for preventing or treating cancer and its usage |
| 02/09/2005 | CN1188111C Dry powder compositions having improved dispersivity |
| 02/08/2005 | US6852839 Fhm, a novel member of the TNF ligand supergene family |
| 02/08/2005 | US6852837 Nucleotide sequences coding protein for use in the treatment nflammatory bowel disease, sepsis, viral diseases and rheumatoid arthritis |
| 02/08/2005 | US6852835 DNA molecules and polypeptides of Pseudomonas syringae Hrp pathogenicity island and their uses |
| 02/08/2005 | US6852755 This invention pertains to nitrogen mustard compounds (Formula (II)) and prodrugs therefor (Formula (I)), methods for their preparation, pharmaceutical compositions comprising such compounds, and the use of such compounds and |
| 02/08/2005 | US6852751 Difluorobutyric acid metalloprotease inhibitors |
| 02/08/2005 | US6852738 Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, |
| 02/08/2005 | US6852735 Novel siastatin B derivative having a potent inhibitory activity against a glycosidase, are now synthesized by new processes. The a potent enzyme inhibitory activity to a glycosidase, which is particularly N- |
| 02/08/2005 | US6852729 Macrolides |
| 02/08/2005 | US6852727 Inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases. |
| 02/08/2005 | US6852725 Imidazolyl derivatives |
| 02/08/2005 | US6852720 Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| 02/08/2005 | US6852715 Formula (1) wherein R1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms; and R2 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon |
| 02/08/2005 | US6852712 Controlling cell differentiation; antiinflammatory agents |
| 02/08/2005 | US6852703 A vector comprising a nucleotide sequence of interest ("NOI") encoding a product of interest ("POI") is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI |
| 02/08/2005 | US6852533 For making vectors for gene therapy |
| 02/08/2005 | US6852528 Human and mouse uroplakin II gene transcriptional regulatory elements |
| 02/08/2005 | US6852522 Methods and interferon deficient substrates for the propagation of viruses |
| 02/08/2005 | US6852520 DSP-2 dual-specificity phosphatase |
| 02/08/2005 | US6852320 T cell inhibitory receptor compositions and uses thereof |
| 02/08/2005 | US6852316 Cancer treatment |
| 02/08/2005 | US6852314 IFN-β liquid formulations |
| 02/08/2005 | CA2287316C Process for preparing 6-o-monoesters of castanospermine |
| 02/03/2005 | WO2005010189A1 OLIGONUCLEOTIDE INHIBITING THE EXPRESSION OF StAR-BINDING PROTEIN (SBP) GENE AND METHOD THEREFOR |
| 02/03/2005 | WO2005010185A1 Rna capable of inhibiting expression of klf5 gene |
| 02/03/2005 | WO2005010169A2 High throughput or capillary-based screening for a bioactivity or biomolecule |
| 02/03/2005 | WO2005010047A2 Antiangiogenic compounds, pharmaceutical composition containing said compounds and the use thereof |
| 02/03/2005 | WO2005010042A1 7a5/prognostin and use thereof for the diagnostic and therapy of tumors |
| 02/03/2005 | WO2005010020A1 Indolopyrrolocabazole derivative and antitumor agent |
| 02/03/2005 | WO2005010019A1 Crystalline 6-n-pyridylmethylaminoindolocarbazole compounds |
| 02/03/2005 | WO2005010018A1 Crystalline 6-n-pyridylmethylaminoindolocarbazoles |